Mild to moderate aortic stenosis and coronary bypass surgery  by Du, Xin & Soon, Jia Lin
Journal of Cardiology (2011) 57, 31—35
avai lab le at www.sc iencedi rec t .com
journa l homepage: www.e lsev ier .com/ locate / j j cc
Review
Mild to moderate aortic stenosis and coronary bypass
surgery
Xin Du (MD)a,∗, Jia Lin Soon (MD)b
a Department of Cardiology, Tianjin Medical University General Hospital, 154, Anshan Road, Heping District,
Tianjin 300052, PR China
b Department of Cardiothoracic Surgery, National Heart Centre, Singapore
Received 3 April 2010; received in revised form 29 May 2010; accepted 26 July 2010
Available online 16 September 2010
KEY WORDS
Aortic stenosis;
Coronary bypass
surgery;
Aortic valve
replacement
Summary
Background: Aortic stenosis (AS) is the most common valvular disease in adult cardiac surgery
and its incidence continues to rise. Increasingly older patients are being referred for coronary
artery bypass grafting (CABG) with mild to moderate AS. Concomitant aortic valve replacement
(AVR) for patients with moderate or severe AS undergoing CABG is warranted regardless of
symptoms. Concomitant AVR remains contentious in patients with less than moderate severity
AS undergoing CABG.
Materials and methods: We review the contemporary literature aiming to resolve this dilemma
in clinical practice. The assessment of these patients is reviewed. Considerations include iden-
tifying the rapid progressors, and balancing the risks of concomitant valve surgery against the
potential prognostic gains.
Results: Pathophysiological links between degenerative calciﬁc AS and coronary artery disease
suggest that the disease is an active, progressive process with mutually shared risk factors.
Statins, however, offer limited protection against AS, despite its established role in coronary
artery disease. Age, atherosclerosis risk, valve morphology, motion, and hemodynamics identify
the rapid progressors, whilst the patients’ general comorbidities and life expectancy inﬂuence
the risk-beneﬁt proﬁle of concomitant operations.
Conclusion: A precise echocardiographic quantiﬁcation of the stenotic grade is mandatory
before adopting any therapeutic strategy. Concomitant AVR for moderate AS is recommended
if surgical risk is not prohibitive. Concomitant AVR for mild AS in ‘rapid progressors’ (i.e.
moderate-severe valve calciﬁcation) may be considered, but patients should have reasonable5 yelife expectancy exceeding
of >10mmHg per year, and ao
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ntroduction
ortic stenosis (AS) is the most common valvular heart dis-
ase that can cause heart failure and sudden death. The
008 American College of Cardiology/American Heart Asso-
iation (ACC/AHA) practice guideline deﬁnes mild AS as
valve area more than 1.5 cm2, mean gradient less than
5mmHg, or jet velocity less than 3.0m/s. AS is considered
oderate if the valve area is 1.0—1.5 cm2, mean gradient is
5—40mmHg, or jet velocity is 3.0—4.0m/s [1]. Since the
rst successful aortic valve replacement (AVR) implanted in
he sub-coronary position in 1960 [2], AVR has become a
ommon operation second only to coronary artery bypass
rafting (CABG). The quality of life and long-term survival
f patients suffering from severe symptomatic AS are signif-
cantly improved by AVR [1,3]. Concomitant AVR for patients
ith moderate or severe AS undergoing CABG is warranted
egardless of symptoms [1,3]. However concomitant AVR in
atients with mild to moderate AS undergoing CABG remains
ontroversial [4]. Increasingly, these older patients are being
eferred for CABG with mild to moderate AS. We review the
ontemporary literature aiming to resolve this dilemma in
ur routine clinical practice.
athophysiological links between degenerative
alciﬁc AS and coronary artery disease
he common causes of AS include rheumatic fever, bicuspid
ortic valve, and degenerative calciﬁcation. AS caused by
ge-related degenerative calciﬁcation is currently the most
ommon reason for AVR in adult cardiac surgery [5]. Its pro-
ression correlates with many risk factors of coronary artery
isease, such as hypertension, advanced age, elevated
erum levels of low-density lipoprotein (LDL) cholesterol and
ipoprotein(a), diabetes, and smoking [6—9].
Senescent or degenerative calciﬁc AS is a progressive
rocess mediated by chronic inﬂammation, which is sim-
lar to atherosclerosis for coronary artery disease. LDL
holesterol level also signiﬁcantly affects the progression
f both coronary artery and aortic valve calciﬁcation [8].
he proliferative and inﬂammatory changes, with lipid accu-
ulation, up-regulation of angiotensin-converting enzyme
ACE) activity, and inﬁltration of macrophages and T lym-
hocytes, contribute to aortic valve calciﬁcation [10]. They
ay potentially become the targets of molecular therapy
mation [11]. Despite promising results of statins in an
animal study [12], a recent randomized, double-blind multi-
centre trial, involving 1873 patients with mild to moderate
asymptomatic AS receiving either simvastatin and ezetim-
ibe, or placebo, has failed to show a positive effect on
AS. At median follow-up of 52.2 months, the incidence of
ischemic cardiovascular events was reduced, with no sig-
niﬁcant change in events related to AS [13]. This may be
partially explained by Antonini-Canterin et al.’s ﬁndings that
statins can only slow the progression of aortic valve disease
in patients with aortic sclerosis or mild AS [14], and that
statins also stimulate bone cell calciﬁcation and ossiﬁcation
of the aortic valve [15].
Progression and prognosis of AS
Patients with mild and moderate AS may have a worse
outcome than previously realized [16]. Nearly half of the
patients with initially mild to moderate AS have rapid pro-
gression [16,17]. Hence knowing the rate of AS progression
becomes important, although predicting it remains difﬁcult
in each individual [9,16]. The aortic valve area decreases
by approximately 0.1 cm2 per year and the peak instanta-
neous gradient increases by 10mmHg per year in patients
with acquired AS [18]. Palta and colleagues [9] showed that
mild AS has a greater annual reduction in valve area, and
that smoking, hypercholesterolemia, and elevated serum
creatinine and calcium levels can accelerate this progres-
sion. They reported the mean rate of AS progression of
0.10± 0.27 cm2 or 7± 18% per year, but this wide conﬁdence
interval makes prediction of progression in any given patient
practically impossible.
Rosenhek et al. [16] followed consecutive asymptomatic
patients with mild to moderate AS for 48± 9 months. They
found 46% of these patients had progressive valve calci-
ﬁcation leading to severe AS and 18% of these patients
underwent AVR due to the onset of symptoms. Moderate
to severe aortic valve calciﬁcation, coronary artery dis-
ease, and peak jet velocity were independent predictors of
outcome; the average rate of increase in aortic jet veloc-
ity was 0.24± 0.30m/s per year. Otto and colleagues [19]
prospectively followed 123 patients with asymptomatic AS,
and found aortic jet velocity to increase by 0.32± 0.34m/s
per year and mean gradient by 7± 7mmHg per year; valve
area decreased by 0.12± 0.19 cm2 per year. The jet velocity,or AS, having already been used to treat coronary artery
isease [10]. The HMG-CoA reductase inhibitors (statins)
revent cardiovascular disease by lowering lipid, improving
ndothelial function, modulating inﬂammatory responses,
aintaining plaque stability, and preventing thrombus for-
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pate of change in jet velocity, and patient’s functional status
ere predictors for the rate of AS progression and clinical
utcome [19].
The rate of AS progression may be more rapid in elderly
atients [8,17,20]. Kume et al. [20] reported more rapid
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rate of reduction of aortic valve area in octogenarians, with
age being the sole independent predictor for progression.
In younger patients (mean age of 55.2± 15.7 years), Piper
and colleagues [21] found aortic valve opening area and the
degree of valvular calciﬁcation to predict AS progression,
but not age. Additionally, AS progression is accelerated in
patients undergoing dialysis with aortic valve calciﬁcation
than those without aortic valve calciﬁcation [22].
Beneﬁts and risks of concomitant AVR in
patients undergoing coronary bypass surgery
Wong et al. [23], in 1993, highlighted the dilemma asso-
ciated with the management of mild to moderate AS in
patients undergoing coronary bypass surgery. Concomitant
AVR in moderate AS is generally acceptable today (class IIa
indication in the 2008 ACC/AHA guidelines [1]). AVR is how-
ever a class IIb indication for mild AS in the presence of signs
suggesting rapid progression (i.e. moderate-severe valve
calciﬁcation) [1]. ‘‘Prophylactic’’ AVR remains controver-
sial. Patients undergoing concomitant AVR and CABG, may
have increased operative and 10-year mortality, especially
in the elderly population [4,24]. Prosthetic valve-related
complications, such as embolism, endocarditis, and bleed-
ing associated with anticoagulation may potentially occur
[23,24]. Nevertheless the increased duration of cardiac
ischemia during a combined AVR and CABG, is generally well
tolerated with modern myocardial protection strategies,
resulting in little or no adverse effect on surgical mortality
[25—27].
On the contrary, if AVR is not performed at the time
of CABG, progression from mild AS occurs at a rapid rate
in about half of these patients [16,17]. The subsequent
need for AVR has been reported to occur at a mean inter-
val of 4—9 years [28—31]. The technical challenge with
AVR subsequent to previous CABG is twofold: (1) avoiding
injury of patent grafts particularly the internal mammary
artery; and (2) myocardial protection [29,32]. Conventional
AVR uniformly requires aortic clamping on cardiopulmonary
bypass, unless circulatory arrest is used. The patent internal
mammary artery graft is dissected and clamped to prevent
regional myocardial warming and cardioplegia ‘‘washout’’
during aortic clamping [29]. The perioperative mortality
ranges between 10% and 16% [30,33,34]. Small series of this
rare cohort of patients have also reported no perioperative
deaths, with satisfactory long-term results [27,35].
Rapid progressors among the patients with mild to mod-
erate AS are identiﬁed by higher transvalvular gradient and
calciﬁed valves [36,37]. Whilst efforts continue to reﬁne this
imprecise science of identifying ‘rapid progressors,’ two fur-
ther considerations exist in our modern clinical landscape:
(1) can percutaneous coronary revascularization ‘temporise’
whilst we monitor the ‘rate of progression’ of AS? [38]; and
(2) transcatheter aortic valve implantation may prove to be
an option in future patients post-CABG, obviating the need
for ‘high-risk’ resternotomy AVR [39].Therapeutic strategy
It is of paramount importance to accurately quantify the
degree of valvular stenosis before adopting any therapeutic
t
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p33
trategy. Currently, Doppler echocardiography is the most
mportant tool to evaluate the heart valves. The maxi-
um jet velocity, mean transvalvular pressure gradient,
nd continuity equation valve area, measured by Doppler
chocardiography are used to evaluate the severity of the
tenosis. Although there is good correlation in the aortic
alvular gradient measured between Doppler echocardiogra-
hy and cardiac catheterization, we need to remember that
chocardiographic ﬁndings are operator dependent. There
re pitfalls that mask the real severity of AS. It is easy to
nderestimate the stenosis due to a nonparallel intercept
ngle between the ultrasound beam and the transvalvu-
ar high velocity jet [1]. On the other hand, a relatively
ow transvalvular pressure gradient may be due to low car-
iac output consequent to impaired left ventricular systolic
unction, especially in patients with severe coronary artery
isease [40]. In this situation, a signiﬁcant AS may be missed
nless a stress test is undertaken. Intravenous dobutamine
tress echocardiography may identify the real degree of AS
40].
The second issue to consider is the all important rate
f AS progression. A rapid rate of progression always leads
o a poor prognosis. Therefore, previous echocardiographic
xaminations provide an idea of the rate with which AS
rogresses. It is also affected by etiology, valve morphol-
gy, and motion. Rheumatic AS has a slower progression and
ess calciﬁcation than degenerative calciﬁc AS [1]. AS with
reater than mild degree of leaﬂet calciﬁcation always has
rapid progression [28,33,41]. Some surgeons attempt to
ecalcify the valve to slow AS progression, but outcome has
een disappointing because of subsequent aortic re-stenosis
nd insufﬁciency [42,43]. Decalciﬁed valves have a higher
otential for re-calciﬁcation than normal, due to its ﬁbril-
ar structure that tends to rapidly accumulate calcium [44].
itz et al. also found moderate leaﬂet motion impairment
o predict rapid AS progression [28,41]. We also need to
onsider the patient’s age and life expectancy. Peter and
olleagues [17] found the ‘rapid progressors’ to be signiﬁ-
antly older and more likely to have concomitant coronary
rtery disease.
Smith et al. [45] used the Markov decision analysis to
ssess the relative beneﬁts of prophylactic AVR at the time
f CABG. They suggest that the decision to perform prophy-
actic AVR should be based on patient age and AS severity, if
he rate of AS progression is average. AVR for mild AS is pre-
erred if the peak valve gradient is more than 25—30mmHg
n patients whose age is under 70 years. This peak valve gra-
ient threshold increases by 1—2mmHg per year in older
atients. AVR is not necessary in patients with mild AS if
S progression is less than 3mmHg per year. However, con-
omitant AVR is preferred when the rate of AS progression
xceeds 10mmHg per year. Sareyyupoglu et al. [27] found
low likelihood of reoperation for AVR during the ﬁrst 5
ears post-CABG, in patients with mild AS (mean gradient
0mmHg) at the time of index operation. Therefore, con-
omitant AVR is not warranted if life expectancy is below 5
ears.The novel technique of transcatheter aortic valve implan-
ation (TAVI) offers a minimally invasive approach, avoiding
ternotomy and extracorporeal circulation and is becom-
ng a viable alternative to conventional AVR for high-risk
atients with AS [46]. Two devices, the Edwards SAPIEN valve
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Edwards Lifesciences, Irvine, CA, USA) and the Medtronic
oreValve ReValving System (Medtronic, Minneapolis, MN,
SA) have received CE approval and have been used in over
,000 patients worldwide [47]. Despite the high incidence
f paravalvular regurgitation, TAVI has resulted in dramatic
emodynamic improvements, providing positive effects on
eft ventricular remodeling and improved neurohormonal
ctivity, myocardial hypertrophy, and diastolic function [48].
herefore, high-risk patients may beneﬁt from this novel
echnique in the future, should their AS progress having not
ad an AVR at the time of coronary bypass surgery.
onclusion
he growing ageing population ensures that we will
ncreasingly manage more elderly patients with less than
oderate-severe AS at the time of presentation for surgi-
al coronary revascularization. The priority of management
emains with the ischemic disease, but we should not miss
he opportunity to change the aortic valve when indicated.
he precise quantiﬁcation of the aortic stenosis is manda-
ory. Concomitant AVR for moderate AS is recommended if
urgical risk is not prohibitive. Concomitant AVR for mild
S in ‘rapid progressors’ (i.e. moderate-severe valve cal-
iﬁcation) may be considered, but patients should have
easonable life expectancy exceeding 5 years. Moderately
estricted leaﬂet motions, gradient increase of >10mmHg
er year, and aortic jet velocity increase >0.4m/s per
ear further supports intervention. Comorbidities increas-
ng atherosclerotic burden and renal dialysis accelerate AS
rogression and increase surgical risk. Procedural advances
n interventional cardiology and minimally invasive cardiac
urgery may further expand the options available for these
atients.
eferences
[1] Bonow RO, Carabello BA, Chatterjee K, de Leon Jr AC, Faxon
DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT,
O’Rourke RA, Otto CM, Shah PM, Shanewise JS. 2008 focused
update incorporated into the ACC/AHA 2006 guidelines for the
management of patients with valvular heart disease: a report
of the American College of Cardiology/American Heart Associ-
ation Task Force on Practice Guidelines (Writing Committee to
revise the 1998 guidelines for the management of patients with
valvular heart disease) endorsed by the Society of Cardiovas-
cular Anesthesiologists, Society for Cardiovascular Angiography
and Interventions and Society of Thoracic Surgeons. Circulation
2008;118:e523—61.
[2] Harken DE, Soroff HS, Taylor WJ, Lefemine AA, Gupta SK, Lun-
zer S. Partial and complete prostheses in aortic insufﬁciency.
J Thorac Cardiovasc Surg 1960;40:744—62.
[3] Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filip-
patos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P,
Tornos P, Torracca L, Wenink A. Guidelines on the management
of valvular heart disease: the Task Force on the Management of
Valvular Heart Disease of the European Society of Cardiology.
Eur Heart J 2007;28:230—68.
[4] Gillinov AM, Garcia MJ. When is concomitant aortic valve
replacement indicated in patients with mild to moderate
stenosis undergoing coronary revascularization? Curr Cardiol
Rep 2005;7:101—4.
[X. Du, J.L. Soon
[5] Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS.
Association of aortic valve sclerosis with cardiovascular mor-
tality and morbidity in the elderly. N Engl J Med 1999;341:
142—7.
[6] Cuniberti LA, Stutzbach PG, Guevara E, Yannarelli GG, Laguens
RP, Favaloro RR. Development of mild aortic valve steno-
sis in a rabbit model of hypertension. J Am Coll Cardiol
2006;47:2303—9.
[7] Singh R, Strom JA, Ondrovic L, Joseph B, VanAuker MD.
Age-related changes in the aortic valve affect leaﬂet stress dis-
tributions: implications for aortic valve degeneration. J Heart
Valve Dis 2008;17:290—8.
[8] Pohle K, Mäffert R, Ropers D, Moshage W, Stilianakis N, Daniel
WG, Achenbach S. Progression of aortic valve calciﬁcation:
association with coronary atherosclerosis and cardiovascular
risk factors. Circulation 2001;104:1927—32.
[9] Palta S, Pai AM, Gill KS, Pai RG. New insights into the progres-
sion of aortic stenosis: implications for secondary prevention.
Circulation 2000;101:2497—502.
10] Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic
valve stenosis: atheroinﬂammatory process. Curr Opin Lipidol
2007;18:483—91.
11] Furberg CD. Natural statins and stroke risk. Circulation
1999;99:185—8.
12] Rajamannan NM, Subramaniam M, Springett M, Sebo TC,
Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spels-
berg TC. Atorvastatin inhibits hypercholesterolemia-induced
cellular proliferation and bone matrix production in the rabbit
aortic valve. Circulation 2002;105:2660—5.
13] Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB,
Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA,
Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, et
al. Intensive lipid lowering with simvastatin and ezetimibe in
aortic stenosis. N Engl J Med 2008;359:1343—56.
14] Antonini-Canterin F, Hîrs¸u M, Popescu BA, Leiballi E, Piazza
R, Pavan D, Ginghina˘ C, Nicolosi GL. Stage-related effect of
statin treatment on the progression of aortic valve sclerosis
and stenosis. Am J Cardiol 2008;102:738—42.
15] Wu B, Elmariah S, Kaplan FS, Cheng G, Mohler 3rd ER. Para-
doxical effects of statins on aortic valve myoﬁbroblasts and
osteoblasts: implications for end-stage valvular heart disease.
Arterioscler Thromb Vasc Biol 2005;25:592—7.
16] Rosenhek R, Klaar U, Schemper M, Scholten C, Heger M,
Gabriel H, Binder T, Maurer G, Baumgartner H. Mild and mod-
erate aortic stenosis. Natural history and risk stratiﬁcation by
echocardiography. Eur Heart J 2004;25:199—205.
17] Peter M, Hoffmann A, Parker C, Lüscher T, Burckhardt D.
Progression of aortic stenosis. Role of age and concomitant
coronary artery disease. Chest 1993;103:1715—9.
18] Lester SJ, Heilbron B, Gin K, Dodek A, Jue J. The natu-
ral history and rate of progression of aortic stenosis. Chest
1998;113:1109—14.
19] Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy
NL, Kraft CD, Miyake-Hull CY, Schwaegler RG. A prospec-
tive study of asymptomatic valvular aortic stenosisclinical,
echocardiographic, and exercise predictors of outcome. Cir-
culation 1997;95:2262—70.
20] Kume T, Kawamoto T, Okura H, Watanabe N, Toyota E, Neishi
Y, Okahashi N, Yamada R, Yoshida K. Rapid progression of mild
to moderate aortic stenosis in patients older than 80 years. J
Am Soc Echocardiogr 2007;20:1243—6.
21] Piper C, Bergemann R, Schulte HD, Koerfer R, Horstkotte D. Can
progression of valvar aortic stenosis be predicted accurately?
Ann Thorac Surg 2003;76:676—80.
22] Kume T, Kawamoto T, Akasaka T, Watanabe N, Toyota E, Neishi
Y, Wada N, Okahashi N, Yoshida K. Rate of progression of valvu-
lar aortic stenosis in patients undergoing dialysis. J Am Soc
Echocardiogr 2006;19:914—8.
y[
[
[
[
[
[
[
[
[
[
[Mild to moderate aortic stenosis and coronary bypass surger
[23] Wong PS, Davies SW, Youhana A, Wright JE, Magee PG. Coronary
artery bypass surgery and minor aortic stenosis—–to replace or
not to replace? J Heart Valve Dis 1993;2:649—52.
[24] Eslami M, Rahimtoola SH. Prophylactic aortic valve replace-
ment in older patients for mild aortic stenosis during coronary
bypass surgery. Am J Geriatr Cardiol 2003;12:197—200.
[25] Galvin I, Mosieri J, Paneth M, Gibson D. An analysis of isolated
aortic valve surgery and combined procedures in patients over
70 years of age. J Cardiovasc Surg (Torina) 1988;29:577—81.
[26] Lytle BW, Cosgrove DM, Goormastic M, Loop FD. Aortic valve
replacement and coronary bypass grafting for patients with
aortic stenosis and coronary artery disease: early and late
results. Eur Heart J 1988;9(Suppl. E):143—7.
[27] Sareyyupoglu B, Sundt 3rd TM, Schaff HV, Enriquez-Sarano M,
Greason KL, Suri RM, Burkhart HM, Park SJ, Dearani JA, Daly RC,
Orszulak TA. Management of mild aortic stenosis at the time of
coronary artery bypass surgery: should the valve be replaced?
Ann Thorac Surg 2009;88:1224—31.
[28] Eitz T, Kleikamp G, Minami K, Gleichmann U, Körfer R. Aortic
valve surgery following previous coronary artery bypass graft-
ing. Impact of calciﬁcation and leaﬂet movement. Int J Cardiol
1998;64:125—30.
[29] Reber D, Fritz M, Bojara W, Marks P, Laczkovics A, Tossios P.
Aortic valve replacement after previous coronary artery bypass
grafting: experience with a simpliﬁed approach. J Cardiovasc
Surg (Torino) 2007;48:73—7.
[30] Verhoye JP, Merlicco F, Sami IM, Cappabianca G, Lecouls H, Cor-
bineau H, Langanay T, Leguerrier A. Aortic valve replacement
for aortic stenosis after previous coronary artery bypass graft-
ing: could early reoperation be prevented? J Heart Valve Dis
2006;15:474—8.
[31] Phillips BJ, Karavas AN, Aranki SF, Cohn LH, Rawn JD, Mihal-
jevic T, Byrne JG. Management of mild aortic stenosis during
coronary artery bypass surgery: an update, 1992—2001. J Card
Surg 2003;18:507—11.
[32] Nakajima M, Tsuchiya K, Fukuda S, Morimoto H, Mitsumori Y,
Kato K. Aortic operation after previous coronary artery bypass
grafting: management of patent grafts for myocardial protec-
tion. Jpn J Thorac Cardiovasc Surg 2006;54:155—9.
[33] Christiansen S, Autschbach R. Perioperative risk of aortic valve
replacement after coronary artery bypass grafting. Thorac Car-
diovasc Surg 2006;54:157—61.
[34] Fiore AC, Swartz MT, Naunheim KS, Moroney DA, Canvasser DA,
McBride LR, Peigh PS, Kaiser GC, Willman VL. Management
of asymptomatic mild aortic stenosis during coronary artery
operations. Ann Thorac Surg 1996;61:1693—7.
[35] Fiore AC, Swartz MT, Naunheim KS, Moroney DA, Canvasser DA,
McBride LR, Peigh PS, Kaiser GC, Willman VL. Safety of remote
aortic valve replacement after prior coronary artery bypass
grafting. Ann Thorac Surg 1996;61:1689—91.
[36] Pereira JJ, Balaban K, Lauer MS, Lytle B, Thomas JD, Garcia
MJ. Aortic valve replacement in patients with mild or mod-
[35
erate aortic stenosis and coronary bypass surgery. Am J Med
2005;118:735—42.
37] Tam JW, Masters RG, Burwash IG, Mayhew AD, Chan KL.
Management of patients with mild aortic stenosis under-
going coronary artery bypass grafting. Ann Thorac Surg
1998;65:1215—9.
38] Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes
DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass
EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW, SYN-
TAX Investigators. Percutaneous coronary intervention versus
coronary-artery bypass grafting for severe coronary artery dis-
ease. N Engl J Med 2009;360:961—72.
39] Walther T, Falk V, Borger MA, Kempfert J, Ender J, Linke
A, Schuler G, Mohr FW. Transapical aortic valve implantation
in patients requiring redo surgery. Eur J Cardiothorac Surg
2009;36:231—4.
40] Rahimtoola SH. Severe aortic stenosis with low systolic gradi-
ent: the good and bad news. Circulation 2000;101:1892—4.
41] Eitz T, Kleikamp G, Minami K, Körfer R. The prognostic value
of calciﬁcation and impaired valve motion in combined aor-
tic stenosis and coronary artery disease. J Heart Valve Dis
2002;11:713—8.
42] McBride LR, Naunheim KS, Fiore AC, Harris HH, Willman VL,
Kaiser GC, Pennington DG, Labovitz AJ, Barner HB. Aortic valve
decalciﬁcation. J Thorac Cardiovasc Surg 1990;100:36—42.
43] Freeman WK, Schaff HV, Orszulak TA, Tajik AJ. Ultrasonic aortic
valve decalciﬁcation: serial Doppler echocardiographic follow-
up. J Am Coll Cardiol 1990;16:623—30.
44] Dahm M, Dohmen G, Groh E, Krummenauer F, Hafner G, Mayer
E, Hake U, Oelert H. Decalciﬁcation of the aortic valve does not
prevent early recalciﬁcation. J Heart Valve Dis 2000;9:21—6.
45] Smith 4th WT, Ferguson Jr TB, Ryan T, Landolfo CK, Peterson
ED. Should coronary artery bypass graft surgery patients with
mild or moderate aortic stenosis undergo concomitant aortic
valve replacement? A decision analysis approach to the surgical
dilemma. J Am Coll Cardiol 2004;44:1241—7.
46] Vahanian A, Alﬁeri O, Al-Attar N, Antunes M, Bax J, Cormier
B, Cribier A, De Jaegere P, Fournial G, Kappetein AP, Kovac
J, Ludgate S, Maisano F, Moat N, Mohr F, et al. Transcatheter
valve implantation for patients with aortic stenosis: a position
statement from the European Association of Cardio-Thoracic
Surgery (EACTS) and the European Society of Cardiology
(ESC), in collaboration with the European Association of Per-
cutaneous Cardiovascular Interventions (EAPCI). Eur Heart J
2008;29:1463—70.
47] Zajarias A, Cribier AG. Outcomes and safety of percutaneous
aortic valve replacement. J Am Coll Cardiol 2009;53:1829—
36.
48] Gotzmann M, Lindstaedt M, Bojara W, Mügge A, Germing
A. Hemodynamic results and changes in myocardial function
after transcatheter aortic valve implantation. Am Heart J
2010;159:926—32.
